Geneva Capital Management LLC Sells 4,598 Shares of Vericel Co. (NASDAQ:VCEL)

Geneva Capital Management LLC cut its holdings in Vericel Co. (NASDAQ:VCEL) by 0.4% in the fourth quarter, HoldingsChannel reports. The firm owned 1,099,788 shares of the biotechnology company’s stock after selling 4,598 shares during the quarter. Geneva Capital Management LLC’s holdings in Vericel were worth $60,389,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Atria Investments Inc boosted its stake in Vericel by 2.4% during the fourth quarter. Atria Investments Inc now owns 7,952 shares of the biotechnology company’s stock worth $437,000 after buying an additional 184 shares during the period. Louisiana State Employees Retirement System raised its holdings in shares of Vericel by 0.8% in the fourth quarter. Louisiana State Employees Retirement System now owns 23,900 shares of the biotechnology company’s stock valued at $1,312,000 after acquiring an additional 200 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in shares of Vericel by 48.1% in the third quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock valued at $53,000 after acquiring an additional 405 shares in the last quarter. Linden Thomas Advisory Services LLC raised its holdings in shares of Vericel by 1.1% in the fourth quarter. Linden Thomas Advisory Services LLC now owns 43,781 shares of the biotechnology company’s stock valued at $2,404,000 after acquiring an additional 489 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. raised its holdings in Vericel by 3.3% in the fourth quarter. Oppenheimer Asset Management Inc. now owns 16,367 shares of the biotechnology company’s stock worth $899,000 after purchasing an additional 517 shares in the last quarter.

Insider Buying and Selling at Vericel

In other Vericel news, Director Robert L. Md Zerbe sold 2,500 shares of the business’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $62.50, for a total transaction of $156,250.00. Following the sale, the director now directly owns 26,595 shares in the company, valued at approximately $1,662,187.50. The trade was a 8.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jonathan Siegal sold 3,908 shares of the business’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $61.99, for a total value of $242,256.92. Following the completion of the transaction, the insider now directly owns 1,206 shares of the company’s stock, valued at approximately $74,759.94. This trade represents a 76.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 7,500 shares of company stock worth $466,200. 5.20% of the stock is currently owned by insiders.

Vericel Stock Up 0.8 %

VCEL opened at $51.53 on Thursday. The firm has a market cap of $2.54 billion, a price-to-earnings ratio of 858.98 and a beta of 1.72. Vericel Co. has a 52 week low of $39.12 and a 52 week high of $63.00. The business’s 50 day moving average is $56.81 and its two-hundred day moving average is $51.93.

Wall Street Analyst Weigh In

A number of equities analysts have commented on VCEL shares. BTIG Research boosted their target price on shares of Vericel from $56.00 to $66.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Stephens reiterated an “overweight” rating and issued a $65.00 target price on shares of Vericel in a research report on Wednesday, January 15th. StockNews.com lowered Vericel from a “hold” rating to a “sell” rating in a research report on Friday, February 28th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Vericel in a research note on Friday, February 28th. Finally, Truist Financial reaffirmed a “buy” rating and set a $61.00 target price (down from $67.00) on shares of Vericel in a research note on Monday. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $62.29.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.